The Safety and Microbial Changes in the Use of Intranasal Neosporin®

NCT07698938 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-07-14

No results posted yet for this study

Summary

Neosporin is an over-the-counter, FDA-approved triple-antibiotic ointment. It is widely used to treat and prevent skin infections following minor burns and injuries. Although the Neosporin® prospect indicates its use is strictly topical, it is often used intranasally by ear, nose, and throat specialists, plastic surgeons, and intensivists to prevent and treat various conditions. Nonetheless, no literature has documented the safety of intranasal Neosporin®. We designed a prospective study to assess the safety of this intervention in healthy participants and to investigate microbial changes before and after the intervention. Healthy participants will apply Neosporin® intranasally for 15 days and record daily adverse events and their severity. Nasal cultures will be drawn before and after the intervention and compared.

Conditions

  • Teste the Safety of (Polymyxin B Sulfate 500,000 IU, Bacitracin Zinc 40,000 IU, Neomycin Sulfate 0.35g Neomycin Base) Intranasally

Interventions

DRUG

Intranasal application of Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base

We want to test the safety of the intranasal application of Neosporin® (Polymyxin B Sulfate 500,000 IU, Bacitracin zinc 40,000 IU, Neomycin Sulfate 0.35g neomycin base) since it has not been tested. Sing and symptom diaries and nasal swabs for culture will be collected

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • Adrian Camacho Ortiz, MD, PhD · Hospital Universitario Dr. José Eleuterio González

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-13
Primary Completion
2025-03-22
Completion
2025-03-23

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07698938 on ClinicalTrials.gov